Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (SE:IMMU)
:IMMU
IMMU Stock Chart & Stats
kr4.91
kr0.08(1.09%)
At close: 4:00 PM EST
kr4.91
kr0.08(1.09%)
Day’s Range― - ―
52-Week Rangekr4.18 - kr10.98
Previous CloseN/A
Volume3.78K
Average Volume (3M)38.75K
Market Cap
€276.05M
Enterprise Valuekr322.57M
Total Cash (Recent Filing)€37.56M
Total Debt (Recent Filing)€4.12M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding52,084,580
10 Day Avg. Volume52,324
30 Day Avg. Volume38,751
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IMMU FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was kr4.17 and its highest was kr10.98 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is €276.05M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is Feb 11, 2026 which is in 58 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Nov 13, 2025. The company reported -kr0.375 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.375.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 52,084,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -kr0.375 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.102%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in SE:IMMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunicum AB
Immunicum AB (IMMU) is a biopharmaceutical company focused on developing innovative, off-the-shelf allogeneic immune therapies for the treatment of solid tumors. The company leverages its proprietary technology platform to stimulate the body's own immune system to recognize and fight cancer cells. Immunicum's lead product candidate, ilixadencel, is a cell-based immune primer currently in clinical development for various cancer indications.
Technical Analysis
Magle Chemoswed Holding AB
―
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Cantargia AB
―